BI-3406, a novel SOS1-KRAS interaction inhibitor designed to target the catalytic domain of SOS1, has been combined with trametinib and sensitized KRAS-driven cancers to MEK inhibition in mouse models. This evidence concerns the gene MAP2K7 and cancer.